CpG Oligodeoxynucleotide (GNKG168)
/ SBI Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 19, 2019
The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study.
(PubMed, Pediatr Hematol Oncol)
- " GNKG168 therapy is associated with immunologic changes in pediatric leukemia patients. Further work with a larger sample size is required to assess the impact of these changes on disease treatment and persistence of leukemia remission."
Journal • P1 data • Residual disease
1 to 1
Of
1
Go to page
1